Crystalline forms of a ras inhibitor
Patent Information
- Application Number
- HK62026125371
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-14
- Filing Date
- 2026-06-26
- Publication Date
- 2026-09-11
Smart Images

Figure 00000055_0000 
Figure 00000056_0000 
Figure 00000057_0000
Abstract
Description
This disclosure is characterized by the crystalline forms of Ras inhibitors, their pharmaceutical compositions, and their use in the treatment of cancer. (Abstract)
Claims
Claims1. A crystalline solid form of Compound A:Compound A or a solvate thereof.
2. The crystalline solid form of claim 1 , wherein Compound A or the solvate thereof is selected from Form 1 , Form 2, Form 3, or Form 4.
3. The crystalline solid form of claim 1 or 2, wherein Compound A or the solvate thereof is Form 1 .
4. The crystalline form of claim 3, having at least one peak at diffraction angle 20 (°) of 4.4 ± 0.5, 4.6 ± 0.5, or 5.1 ± 0.5 as measured by X-ray diffractometry by irradiation with Cu Ka X-rays or calculated from X-ray diffractometry.
5. A mixture of crystalline Forms 1 and 2 of Compound A:Compound A or a solvate thereof, having at least one peak at diffraction angle 20 (°) of 4.4 ± 0.5, 4.6 ± 0.5, or 4.8 ± 0.5 as measured by X-ray diffractometry by irradiation with Cu Ka X-rays or calculated from X-ray diffractometry.
6. A pharmaceutical composition comprising the crystalline forms of Compound A of any one of claims 1 to 5, or a solvate thereof, and a pharmaceutically acceptable carrier or excipient.
7. A method of making crystalline Form 1 or a mixture of crystalline Forms 1 and 2 ofCompound A,Compound A or a solvate thereof, comprising dissolving Compound A in a suitable solvent, precipitating the crystalline form(s) of Compound A by the addition of a suitable antisolvent, isolating the crystalline form(s) of Compound A, and drying the crystalline form(s) of Compound A.
8. A method of making crystalline Form 1 or a mixture of crystalline Forms 1 and 2 of Compound A,Compound A or a solvate thereof, comprising dissolving Compound A in a suitable solvent, precipitating the crystalline form(s) of Compound A by the evaporation of the suitable solvent, isolating the crystalline form(s) of Compound A, and drying the crystalline form(s) of Compound A.
9. A method of making crystalline Form 1 or a mixture of crystalline Forms 1 and 2 of Compound A,Compound A or a solvate thereof, comprising dissolving Compound A in a suitable solvent, precipitating the crystalline form(s) of Compound A under ambient conditions, the isolating the crystalline form(s) of Compound A, and drying of the crystalline form(s) of Compound A.
10. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of crystalline Form 1 or a mixture of crystalline Forms 1 and 2 of Compound A of any one of claims 1 -5, or a solvate thereof, or a pharmaceutical composition of claim 6.
11. A method of treating a Ras protein-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of crystalline Form 1 of Compound A or a mixture of crystalline Forms 1 and 2 of Compound A of any one of claims 1 -5, or a solvate thereof, or a pharmaceutical composition of claim 6.
12. A method of inhibiting a Ras protein in a cell, the method comprising contacting the cell with an effective amount of crystalline Form 1 or a mixture of crystalline Forms 1 and 2 of Compound A of any one of claims 1 -5, or a solvate thereof, or a pharmaceutical composition of claim 6.
13. The method or use of any one of claims 10-12, wherein the method further comprises administering an additional anticancer therapy.
14. The method of claim 13, wherein the additional anticancer therapy is the following:or a pharmaceutically acceptable salt thereof.
